Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study

• DOI: 10.1007/s40268-022-00396-1
• Publication Date: 2022-08-03T16:03:09Z
• Authors: Andrea Chiricozzi; Niccolò Gori; Alessandra Narcisi; Anna Balato; Alessio Gambardella; Michela Ortoncelli; Angelo Valerio Ma...; Riccardo Balestri; Giovanni Palazzo; Michele Pellegrino; Marco Romanelli; Giovanni Tripepi; Ketty Peris; Antonio Costanzo; ; Alberto Maria Ber...; Gabriella Fabbrocini; Maria Concetta Fa...; Giampiero Girolomoni; Aurora Parodi; Pietro Quaglino
• Keywords: Adult; atopic dermatitis; Severity of Illness Index; Dermatitis, Atopic; Cohort Studies; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Quality of Life; Humans; Original Research Article; Prospective Studies; upadacitinib AD; Heterocyclic Compounds, 3-Ring

The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been defined in clinical trials, but no real-world data are currently available. We aimed to assess the safety and effectiveness of upadacitinib in a real-world AD patient cohort that mostly included patients who failed the available systemic therapies, including dupilumab.Prospective cohort study collecting data on upadacitinib-treated AD adult patients completing at least 16 weeks of therapy.Forty-three patients showed rapid and marked response to upadacitinib with significant reduction of all disease severity scores since the first follow-up visit. At week 16, Eczema Area and Severity Index (EASI) 75, EASI 90, and EASI 100 response was observed in 97.5%, 82.1%, and 69.2% of patients, respectively. EASI 90 response reflected the achievement of a clear or almost clear condition (POEM 0-2), self-evaluated by 79.5% of patients. Patients' quality of life improved as suggested by the achievement of DLQI 0/1 by 38.5% of patients at week 4, and by 76.9% at week 16.Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients unresponsive to dupilumab, who were not included in upadacitinib trials.